S. Falk

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

Corinne Faivre‐Finn, S. Falk, Linda Ashcroft et al. · BMJ Open · 2016 · 41 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study

Kate Haslett, K. Franks, Gerard G. Hanna et al. · BMJ Open · 2016 · 28 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey

Antonin Lévy, Lizza Hendriks, C. Le Péchoux et al. · Lung Cancer · 2019 · 28 citations · Full text

Medicine, Oncology, Thoracic Oncology +6

TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy.

S. Lee, R.M. Rudd, Imran Khan et al. · Journal of Clinical Oncology · 2010 · 27 citations

Medicine, Oncology, Pharmacology +12

Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)

Rob Glynne‐Jones, David Sebag‐Montefiore, A. McDonald et al. · Journal of Clinical Oncology · 2004 · 17 citations

Medicine, Oncology, Pharmacotherapy +17